New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
04:55 EDTLGND, LGND, LGND, MDCO, MDCO, MDCO, ESRX, ESRX, ESRX, NPSP, NPSP, NPSP, BDSI, BDSI, BDSI, FEIC, FEIC, FEIC, HUM, HUM, HUM, IDIX, IDIX, IDIX, SYK, SYK, SYK, STE, STE, STE, PRTA, PRTA, PRTABofA/Merrill to hold a conference
2014 Healthcare Conference to be held in Las Vegas on May 13-15.
News For LGND;STE;SYK;IDIX;HUM;FEIC;BDSI;NPSP;ESRX;MDCO;PRTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
09:22 EDTNPSPOn The Fly: Pre-market Movers
Subscribe for More Information
07:12 EDTSYKCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
06:56 EDTNPSPShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
October 17, 2014
07:45 EDTSYKStryker price target lowered to $84 from $88 at Canaccord
Subscribe for More Information
October 16, 2014
16:04 EDTSYKStryker sees FY14 adjusted EPS at low end of $4.75-$4.80 guidance
Subscribe for More Information
16:02 EDTSYKStryker reports Q3 adjusted EPS $1.15, consensus $1.14
Reports Q3 revenue $2.39B, consensus $2.32B.
15:26 EDTSYKNotable companies reporting after market close
Subscribe for More Information
October 14, 2014
12:33 EDTSYKZimmer, Stryker have postive read-through from J&J, says Wells Fargo
Subscribe for More Information
11:11 EDTSYKJohnson & Johnson Ortho strength positive for Zimmer, says Piper Jaffray
Piper Jaffray said Johnson & Johnson's (JNJ) sequential Q3 strength in orthopedics, which included acceleration in both hips and knees, was surprising and a positive for Zimmer (ZMH). However, Piper expect sentiments on ortho names to remain muted until further into reporting season, noting that Stryker (SYK) is scheduled to report Thursday after the close. The firm has Neutral rating on Johnson & Johnson and Stryker and an Overweight rating on Zimmer.
October 13, 2014
07:39 EDTHUM, ESRXPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
07:25 EDTMDCOEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
06:07 EDTSTESteris to host conference call
Subscribe for More Information
05:30 EDTSTESteris to acquires Synergy Health for $1.9B in cash, stock
Subscribe for More Information
05:27 EDTSTESteris to acquires Synergy Health for $1.9B in cash, stock
October 10, 2014
10:01 EDTBDSIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:16 EDTSYKAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
07:14 EDTMDCOThe Medicines Co's Q3 Angiomax estimate lowered at Credit Suisse
Subscribe for More Information
06:02 EDTBDSIBioDelivery Sciences downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 9, 2014
16:57 EDTMDCOThe Medicines Co. announces journal publication of SOLO II phase 3 trial
The Medicines Company announced the publication of the results from the SOLO II phase 3 clinical trial of ORBACTIV, or oritavancin, for injection in the journal Clinical Infectious Diseases. ORBACTIV, is the first and only single dose intravenous antibiotic approved by FDA for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections, or ABSSSI, caused or suspected to be caused by susceptible isolates of designated Gram-positive pathogens. The publication reported that a single, once only, 1200 mg intravenous dose of ORBACTIVTM was non-inferior to twice-daily intravenous dosing of vancomycin given for 7 to 10 days in patients with ABSSSI caused or suspected to be caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. A single 1200 mg IV dose of ORBACTIV results in efficacy in ABSSSIs that is comparable and statistically non-inferior to vancomycin administered intravenously for 7-10 days. ORBACTIV had a safety profile comparable to vancomycin when monitored for up to 60 days following a single dose, with similar intensity, onset and duration of AEs.
06:18 EDTSYKBiomet reports Q1 sales up 6% to $775M
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use